Trevi Posts Wider Q3 Loss, $299.4M Cash Runway Into 2030, ILD Phase 2 Set for Q1 2027
TRVI sits 59% above its 52-week low of $9.82.
Summary
Trevi reported a Q3 2026 net loss of $21.5 million, up from $11.8 million a year ago, while holding $299.4 million in cash and securities with runway into 2030. It also disclosed FDA alignment on a non-IPF ILD Phase 2 trial expected to start in Q1 2027 and a new patent allowance running to 2041.
Key Events · Earnings and Guidance · TRVI
-
Q3 Loss Widens on Trial Costs
Net loss was $21.5 million for Q3 2026 versus $11.8 million in Q3 2025, while R&D rose to $19.1 million from $10.1 million as the OCEAN-1, OCEAN-2 and LAKE trials scaled up.
-
Cash Runway Into 2030
The company ended September 30, 2026 with $299.4 million in cash, cash equivalents and marketable securities, which it says funds development through potential FDA approval in IPF-related chronic cough.
-
ILD Phase 2 Set for Q1 2027
A positive October 2026 FDA meeting aligned the non-IPF ILD chronic cough program on a Phase 2 dose-ranging trial of 54 mg and 27 mg BID versus placebo in roughly 120 patients, targeted to start in Q1 2027 with topline in H1 2028.
-
Patent Allowance to 2041
USPTO issued a Notice of Allowance for claims covering nalbuphine ER dosing in hepatically impaired non-IPF ILD patients; the patent is expected to expire in 2041 and may be Orange Book listable.
Analysis · TRVI · Life Sciences
The widening loss is the quarter's headline: net loss of $21.5 million versus $11.8 million a year ago, as the Phase 3 OCEAN-1, OCEAN-2 and Phase 2b LAKE trials ramp up. That spending is fully funded, with $299.4 million in cash and marketable securities at September 30, 2026 supporting runway into 2030, so there is no near-term financing need despite the burn. More durable is the clinical news: a positive FDA meeting aligned the non-IPF ILD chronic cough program on a Phase 2 design (two doses, ~120 patients) targeted for a Q1 2027 start, and a new USPTO allowance extends dosing patent protection in hepatically impaired ILD patients to 2041. The nearest scheduled data point is the RCC LAKE trial's sample-size re-estimation readout, which has slipped to early Q1 2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRVI was trading at $15.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.82 to $20.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.